Biotech Values

[DewDiligence]

MNTA: The potential milestones from NVS attributable to M178 comprised only 8% ($15M) of the $178M of potential milestones payable by NVS under the companies’ amended 2006 collaboration:

http://sec.gov/Archives/edgar/data/1235010/000110465909070614/a09-35662_18k.htm

Although today’s SEC filing says that some of the $15M attributable to M178 could still be received, I don’t think investors should count on it. Thus, the realistic milestone figure from the 2006 NVS collaboration is now $163M, which consists of milestones pertaining to Lovenox and Copaxone.